Table S1 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Q: What type of study is this?

This is a Experimental Study study.

Zahra Davoudi; Thomas S. Dexheimer; Nathan P. Coussens; Thomas Silvers; Raymond G. Fox; Samantha B. Kemp; Punita Juneja; Joel Morris; Melinda G. Hollingshead; Naoko Takebe; James H. Doroshow; Beverly A. Teicher

doi:10.1158/2767-9764.30304669

October 8, 2025Open Access

Table S1 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

View Full Paper

Ask AI

Bookmark

Share

Key Points

RAS pathway inhibitors and targeted agents demonstrated significant activity in patient-derived spheroids with oncogenic KRAS variants.
The analysis details the array of drugs used, including RAS pathway inhibitors and their combined effect with targeted agents in multiple cancer types.
This research utilized patient-derived spheroids as a model to assess drug efficacy against oncogenic mutations.
The findings highlight the potential of combining targeted therapy with RAS pathway inhibition for treating cancers with KRAS variants.

Implication

This analysis reports on the activity of RAS pathway inhibitors and targeted agents in patient-derived spheroids, suggesting potential treatment avenues for cancer.

Abstract

Table S1. Drugs and investigational agents used in this study. The agents included RAS pathway inhibitors (top) and molecular targeted combination drugs (bottom). If available at the time of this study, the clinical Cmax is listed.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3bc4 https://doi.org/10.1158/2767-9764.30304669

View Full Paper

Ask AI

Bookmark

Share

Table S1 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Table S1 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading